Viatris Inc.

9.69+0.0800+0.83%Vol 8.83M1Y Perf -12.08%
Dec 6th, 2023 16:00 DELAYED
BID9.66 ASK9.70
Open9.64 Previous Close9.61
Pre-Market- After-Market9.60
 - -  -0.09 -0.93%
Target Price
12.89 
Analyst Rating
Moderate Sell 3.60
Potential %
33.02 
Finscreener Ranking
★★★     49.00
Insiders Trans % 3/6/12 mo.
-/100/100 
Value Ranking
★★+     47.98
Insiders Value % 3/6/12 mo.
-/100/100 
Growth Ranking
★★+     49.59
Insiders Shares Cnt. % 3/6/12 mo.
-/100/100 
Income Ranking
★★     37.21
Price Range Ratio 52W %
25.96 
Earnings Rating
Market Cap11.62B 
Earnings Date
7th Nov 2023
Alpha-0.03 Standard Deviation0.11
Beta1.09 

Today's Price Range

9.629.79

52W Range

8.7412.40

5 Year PE Ratio Range

-10.80770.30

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
5.56%
1 Month
6.13%
3 Months
-3.10%
6 Months
-0.21%
1 Year
-12.08%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
VTRS9.690.08000.83
AAPL192.32-1.1000-0.57
GOOG131.43-0.9600-0.73
MSFT368.81-3.7150-1.00
XOM99.11-1.3300-1.32
WFC44.500.01000.02
JNJ156.62-1.9300-1.22
FB196.640.99000.51
GE119.81-0.4200-0.35
JPM156.31-1.6600-1.05
Financial StrengthValueIndustryS&P 500US Markets
0.70
1.60
0.49
1.02
2.90
Leverage Ratio 2.60
ProfitabilityValueIndustryS&P 500US Markets
37.10
10.40
27.70
0.20
8.62
RevenueValueIndustryS&P 500US Markets
12.39B
10.21
15.57
7.31
Earnings HistoryEstimateReportedSurprise %
Q03 20230.740.785.41
Q02 20230.710.755.63
Q01 20230.690.7813.04
Q04 20220.690.690.00
Q03 20220.820.864.88
Q02 20220.810.888.64
Q01 20220.810.9314.81
Q04 20210.820.80-2.44
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report0.74
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume8.83M
Shares Outstanding1.20M
Shares Float1.20B
Trades Count39.36K
Dollar Volume85.64M
Avg. Volume8.75M
Avg. Weekly Volume8.92M
Avg. Monthly Volume8.64M
Avg. Quarterly Volume8.69M

Viatris Inc. (NASDAQ: VTRS) stock closed at 9.69 per share at the end of the most recent trading day (a 0.83% change compared to the prior day closing price) with a volume of 8.83M shares and market capitalization of 11.62B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 40000 people. Viatris Inc. CEO is Michael Goettler.

The one-year performance of Viatris Inc. stock is -12.08%, while year-to-date (YTD) performance is -12.94%. VTRS stock has a five-year performance of %. Its 52-week range is between 8.74 and 12.3993, which gives VTRS stock a 52-week price range ratio of 25.96%

Viatris Inc. currently has a PE ratio of 18.30, a price-to-book (PB) ratio of 0.76, a price-to-sale (PS) ratio of 1.18, a price to cashflow ratio of 4.40, a PEG ratio of -, a ROA of 1.53%, a ROC of 2.90% and a ROE of 3.99%. The company’s profit margin is 8.62%, its EBITDA margin is 27.70%, and its revenue ttm is $12.39 Billion , which makes it $10.21 revenue per share.

Of the last four earnings reports from Viatris Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.74 for the next earnings report. Viatris Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Viatris Inc. is Moderate Sell (3.6), with a target price of $12.89, which is +33.02% compared to the current price. The earnings rating for Viatris Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Viatris Inc. has a dividend yield of 4.00% with a dividend per share of $0.48 and a payout ratio of -%.

Viatris Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 21.56, ATR14 : 0.23, CCI20 : 168.95, Chaikin Money Flow : 0.02, MACD : 0.04, Money Flow Index : 63.31, ROC : 4.80, RSI : 58.22, STOCH (14,3) : 77.94, STOCH RSI : 0.85, UO : 61.73, Williams %R : -22.06), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Viatris Inc. in the last 12-months were: Andrew Cuneo (Option Excercise at a value of $0), Anthony Mauro (Option Excercise at a value of $0), Brian Roman (Option Excercise at a value of $0), Der Meer Mohr Pauline Van (Option Excercise at a value of $0), Dillon JoEllen Lyons (Option Excercise at a value of $0), Harry A. Korman (Option Excercise at a value of $0), James M. Kilts (Option Excercise at a value of $0), Mark W. Parrish (Option Excercise at a value of $0), Melina E. Higgins (Option Excercise at a value of $0), Michael Goettler (Option Excercise at a value of $0), Paul B. Campbell (Option Excercise at a value of $0), Pauline F.M. van der Meer Mohr (Option Excercise at a value of $0), Rajiv Malik (Option Excercise at a value of $0), Richard A. Mark (Option Excercise at a value of $0), Robert J. Coury (Option Excercise at a value of $0), Sanjeev Narula (Option Excercise at a value of $0), Wyllie Don Cornwell (Option Excercise at a value of $0), Xiangyang (Sean) Ni (Option Excercise at a value of $0), Xiangyang (Sean) Ni (Sold 26 428 shares of value $268 324 ), Xiangyang Ni (Option Excercise at a value of $0), Xiangyang Ni (Sold 11 491 shares of value $128 363 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
1 (16.67 %)
1 (16.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (60.00 %)
3 (50.00 %)
4 (66.67 %)
Moderate Sell
1 (20.00 %)
1 (16.67 %)
0 (0.00 %)
Strong Sell
1 (20.00 %)
1 (16.67 %)
1 (16.67 %)
Summary RatingModerate Sell
3.60
Hold
3.17
Hold
3.00

Viatris Inc.

The new entity will largely be led by Pfizer executives and will be registered in Delaware. The new entity is anticipated to leverage the stand-alone Mylan infrastructure consisting of roughly 55 manufacturing and research and development facilities and that were largely acquired, including Matrix Laboratories and the generics business of Germany-based Merck KGaA. The combined portfolio will consist of the mature Upjohn drugs with notably better economics and Mylan's portfolio of more than 7,500 generic, specialty, and over-the-counter active ingredients and medicines, including EpiPen (treatment for anaphylaxis acquired through the Merck KGaA transaction). Unlike its generic peers, the company has made the most progress on the biosimilar front.

CEO: Michael Goettler

Telephone: +1 724 514-1800

Address: 1000 Mylan Boulevard, Canonsburg 15317, PA, US

Number of employees: 40 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

62%38%

Bearish Bullish

53%47%

Bearish Bullish

60%40%

 

TipRanks News for VTRS

Wed, 08 Nov 2023 11:01 GMT Analysts Conflicted on These Healthcare Names: Viatris (VTRS), Globus Medical (GMED) and Gilead Sciences (GILD)

- TipRanks. All rights reserved.

Tue, 08 Aug 2023 07:16 GMT Viatris (VTRS) Receives a Sell from Barclays

- TipRanks. All rights reserved.

News

Stocktwits